The University of British Columbia's Collaboration for Outcomes Research and Evaluation (CORE) group addresses the need for clinical and economic research, and education in pharmaceutical outcomes assessment. The CORE team is a multidisciplinary group of researchers with expertise in clinical pharmacy, pharmacoepidemiology, health economics, health services research, program evaluation and health promotion research. CORE strives to provide evidence which will maximize the clinical, quality of life, and economic benefits of drug therapy, while minimizing associated risks. This is achieved through independent research and research collaborations with pharmaceutical and health outcomes researchers throughout North America and Europe.

Dr. Larry Lynd, Associate Professor at the Faculty of Pharmaceutical Sciences in the University of British Columbia, and his research team are conducting focus group sessions to assess patients’ opinions regarding drug therapies used in MS treatment. Patients with MS who are 19 years old or older are being invited to participate in a 1.5 hour focus group session.

For more information about the study, please contact the research investigators via email at ms-study.core@ubc.ca or by phone at 604 822 5697 or 604 827 3695.